CSF2 and neoplasm: Taking into account the fact that GM-CSF is able to activate and process the presentation of tumor-associated antigens by dendritic cell (DC)s, GM-CSF was studied in clinical trials by overexpressing in tumor cells, but significant therapeutic outcomes were not obtained [4,5].